Abnormalities of mitochondrial energy metabolism may play a role in normal aging and certain neurodegenerative disorders. In this regard, complex I of the electron transport chain has received substantial attention, especially in Parkinson's disease. The conventional method for studying complex I has been quantitation of enzyme activity in homogenized tissue samples. To enhance the anatomic precision with which complex I can be examined, we developed an autoradiographic assay for the rotenone site of this enzyme.
[3H]dihydrorotenone Q3H]DHR) binding is saturable (K, = 15-55 nM) and specific, and Hill slopes of 1 suggest a single population of binding sites. Nicotinamide adenine dinucleotide (NADH) enhances binding 4-to 80-fold in different brain regions (EC, , by increasing the density of recognition sites (B,,,) . Nicotinamide adenine dinucleotide phosphate also increases binding, but NADf does not. In skeletal muscle, heart, and kidney, binding Energy-consuming reactions are fueled by the hydrolysis of phosphate bonds, principally in the form of ATP. The primary mechanism by which this high-energy intermediate is produced can be oxidative or glycolytic, depending on the specific tissue studied. In neurons, ATP is produced primarily during oxidative phosphorylation, although a small quantity is derived from glycolysis (Erecinska and Silver, 1989) .
Oxidative phosphorylation requires the coordinated activity of five enzymes of the inner mitochondrial membrane: complexes I, II, III, IV, and V (Hatefi, 198.5) . The proximal four enzymes, collectively known as the electron transport chain (ETC), convert the potential energy in reduced adenine nucleotides [nicotinamide adenine dinucleotide (NADH) and FADH,] into a form capable of supporting ATP synthase activity. Reducing equivalents (electrons) enter the ETC at two sites: complex I (NADH: ubiquinone oxidoreductase) or complex II (succinate:ubiquinone oxidoreductase) and undergo sequential oxidation-reduction (redox) reactions. Complex I and II reduce ubiquinone (coenzyme Q) to ubiquinol (Cooper and Clark, 1994) . Complex III (ubiqui-was less affected by NADH.
[3H]DHR binding is inhibited by rotenone (IC, , (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , meperidine (IC,, = 34-57 PM), amobarbitol (IC, , , and MPP~' (IC,, = 4-5 mM), consistent with the potencies of these compounds in inhibiting complex I activity. Binding is heterogeneously distributed in brain with the density in gray matter structures varying more than 1 O-fold. Lesion studies suggest that a substantial portion of binding is associated with nerve terminals.
[3H]DHR autoradiography is the first quantitative method to examine complex I with a high degree of anatomic precision. This technique may help to clarify the potential role of complex I dysfunction in normal aging and disease.
Key words: mitochondria; electron transport chain; complex I; [3H]dihydrorotenone; rotenone; MPP+; amobarbitol; autoradiography none:cytochrome c oxidoreductase) couples the oxidation of ubiquinol to cytochrome c reduction (Rieske, 1976) . Complex IV (cytochrome c:oxygen oxidoreductase) catalyzes the oxidation of cytochrome c, ultimately reducing molecular oxygen and producing water (Caughey et al., 1976; Capaldi, 1990) . Potential energy released during redox cycling drives the extrusion of protons across the inner mitochondrial membrane at three sites: complex I, III, and IV. This electrochemical gradient supports the synthesis of ATP by complex V (Caughey et al., 1976; Capaldi et al., 1994) .
Interest in the role of the mitochondrion and especially complex I in neurological disease has surged since the description of 1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) induced parkinsonism (Davis et al., 1979) . A metabolite of MPTP, l-methyl-4-phenylpyridinium (MPP '), is selectively toxic to dopaminergic neurons by inhibiting complex I (Nicklas et al., 19S5) . Moreover, a defect in complex I has been reported in muscle (Bindoff et al., 1989 ) platelets (Shoffner et al., 1991 and brain (Schapira et al., 1990a) in patients with Parkinson's disease. The defect in brain is reportedly restricted to the substantia nigra (Schapira et al., 1990b) ; however, the distribution of complex I in brain has not been described.
Conventional assays of complex I are performed in tissue homogenates or mitochondrial preparations. Anatomical resolution is limited by dissection techniques and the quantity of tissue needed for the assay. Moreover, complex I assays are labile and highly dependent on tissue preparation protocols (Trijbels et al., 1993) . Using an analog of rotenone, the insecticide that defines the catalytic activity of complex I by its inhibition (Cooper and Clark, 1994), we have developed a stable, reproducible, and quan- (200-225 gm) were killed by decapitation, and the brains were rapidly removed, coated with embedding matrix (Lipshaw, Detroit, MI), and frozen under powdered dry ice. Twenty micrometer horizontal sections containing striatum, hippocampus, and cerebellum were used in pharmacological experiments. For distribution studies, coronal sections at 11 levels were examined, 4 anterior (6.70,5.20, 1.70, and 0.20 mm) and 7 posterior to bregma (0.80, 2.30, 3.60, 5.80, 6.80, 10.80, and 13.30 mm) according to the atlas of Paxinos and Watson (1986) . Sections were cut on a cryostat and thaw-mounted onto poly-L-lysine-coated slides. Samples of kidney, heart, and striated muscle were prepared in an identical manner. Slide-mounted tissue sections wcrc stored at -70°C until the time of assay.
/'H]DHR autoradiography.
['H]DHR binding was pcrformcd as described nrcviouslv (Grccnamvrc et al., 1992 to bregma and angled 10" outward with the needle tip at the midline. The needle was then moved 3.25 mm laterally, and a small hole was drilled in the skull to the dura. The needle was lowered 6 mm from the dura and 0.75 ~1 was infused over 3 min; then the needle was raised 1 mm for a second infusion of 0.75 ~1. 
RESULTS

Characterization of [3H]DHR binding
In preliminary experiments, high levels of nonspecific binding prevented accurate determination of specific ["HIDHR binding. As noted by Horgan et al. (1968) , albumin reduced nonspecific binding to -lo-20% of total ["HIDHR binding under routine assay conditions. Therefore, albumin (1%) was included in all experiments; more concentrated solutions did not further reduce nonspecific binding (data not shown). In addition, preliminary experiments showed that ["HIDHR binding reached equilibrium within 2 hr and remained stable for at least 6 hr (data not shown). Thus, a 2 hr incubation was used routinely. Other experiments showed that extensively prewashing tissue sections in buffer for 30-60 min to remove endogenous NADH did not affect binding (data not shown).
As shown previously (Greenamyre et al., 1992) , ["HIDHR binding was saturable with an affinity in the low nanomolar range ( In the presence of 1% albumin at a [3H]DHR concentration of 5 nM, SO-90% of total binding was specific. Effects of adenine nucleotides NADH enhanced [3H]DHR binding in a concentrationdependent manner, with a Hill slope that did not differ significantly from 1 (Fig. 2) . The EC,, was 20-40 PM (Table 1) . As shown in Figure 3, MPP+ with the ["HIDHR binding site was competitive (Fig. 7) . In the dg, the KD and B,;,, were 17.8 -C 4.0 nM and 1.16 t 0.08 pmol/mg tissue in the absence of MPP+, 25.1 ? 5.7 nM and 1.07 f 0.06 pmol/mg tissue in the presence of 1 mM MPP' , and 133.1 2 74.9 nM and 1.79 -C 0.48 pmolimg tissue in the prcscncc of 5 mM MPP' (n = 4).
Regional distribution of [3H]DHR binding
Basal Of the tissues assayed, kidney and heart had, by far, the highest levels of ["HIDHR binding (Fig. 8 , , 1994; 'Earley et al., 1987; 'Filser and Wcrncr, 1988; "Andrcani ct al., 1994; 'Ramsay ct al., 1991. bound in the lateral septum and hippocampal formation. Binding in most structures, including certain thalamic, basal ganglia, and brainstem nuclei, was only 20-30% of that found in the epl. Delineation of specific thalamic nuclei was difficult. A laminar pattern was present in the cerebral cortex, with denser labeling of superficial layers. In contrast, differentiation of lamina within the cerebellar cortex was difficult. Specific binding could not be detected in several regions, mostly in brainstem. There was negligible binding in white matter regions, such as the corpus callosum. vary regionally (Fig. 9, Table 4 ). Only in the renal cortex did C3H]DHR binding increase substantially (174%).
In certain brain structures, including the cerebellar cortex, substantia nigra, and superior colliculus, binding increased 20-fold or more. A minority of brain regions, such as the basolateral amygdala, septum, and reticular nucleus of the thalamus, had a smaller response to NADH (less than lo-fold increase). Of the areas surveyed, the smallest response to NADH, a fourfold increase, occurred in the CA1 pyramidal cell layer, and the most striking potentiation was seen in cmol. Under basal conditions, only four structures contained lesser amounts of [3H]DHR than the cmol. In the presence of 200 PM NADH, only two regions possessed more label, the epl and dg. The distribution of [3H]DHR binding sites in the presence of 200 FM NADH is shown in Figure 10 .
Effects of entorhinal cortex lesions
One week after injection of NMDA into the medial entorhinal cortex (n = 3), there was a modest local decrease in binding (25-30%), particularly in superficial cortical layers, and a more substantial loss of binding (51%; 24.7 ? 4.1 vs 12.2 ? 4.3 fmol/mg tissue; p < 0.05) in the middle one-third of the molecular layer of the dg (Fig. 11) .
DISCUSSION
We developed an autoradiographic binding assay to study complex I using [3H]DHR. Radioligand assays of complex I are not new. In electron transport particle preparations, [r4C]-labeled complex I inhibitors rotenone (Horgan et al., 1968) and piericidin A (Gutman et al., 1970) have been used to probe this enzyme. These earlier studies were hampered by substantial nonspecific binding, which was reduced, although not satisfactorily, by albumin. The low specific activity of [i4C]rotenone (2.36 mCi/mmol), more than 20,000-fold lower than that of [3H]DHR, undoubtedly contributed to the high level of nonspecific binding. As can be seen in Figure 1 , nonspecific binding increases linearly with ligand concentration; however, the high specific activity of [3H]DHR facilitates working at low ligand concentrations at which the signal-to-noise ratio is excellent, and >80% of binding is specific. In contrast, to obtain a reliable signal using [14C]rotenone, much higher concentrations are required, accompanied by a linear increase in nonspecific binding. For example, in the classic study of Horgan et al. (1968) , the lowest concentration of ['4C]rotenone used in the binding assay was -125 nM (estimated from their Fig.  2) , which is higher than the highest concentration of [3H]DHR used in our study. Finally, as discussed below, NADH markedly June 15, 1996, 76(12) In the middle one-third of the molecular layer of the dg, the region to which the lesioned entorhinal neurons project, there is a 50% decrease in binding (thin arrows). Thus, it appears that a substantial portion of complex I is associated with synaptic terminals in this region. B, Unlesioned hemisphere from the same brain.
to-low millimolar range (Ernster et al., 1963) . We found that amobarbitol inhibited [3H]DHR binding with an IC,, of 400 FM, but did not displace -30% of specifically bound [3H]DHR. Unlike rotenone, amobarbitol had Hill slopes of 2-3. MPP+ is a weak complex I inhibitor, having an IC,, of 5-10 mM in submitochondrial particles (Hoppel et al., 1987) and electron transport particles (Ramsay et al., 1987 (Horgan et al., 1968) , we did not find sigmoid binding curves that would suggest multiple, interacting binding sites; however, we did not use the extremely high ligand concentrations of the earlier studies. Moreover, it is possible that [3H]DHR binds to more than one site, each having a very similar affinity. This could produce linear Scatchard plots and Hill slopes of 1. Consistent with this possibility are the steep Hill slopes for amobarbitol and MPP+, which may indicate positive cooperativity of multiple binding sites. MPP+ inhibition of complex I has been suggested to be a two-site process. According to this scheme, MPP+ initially binds to a hydrophilic site accessible to the matrix compartment, resulting in partial inhibition. Subsequent access to a hydrophobic site within the mitochondrial membrane produces complete inhibition (Singer and Ramsay, 1994 closely matches the Km of the enzyme for NADH (Hate& 1985) . Complex I can be resolved into membrane-based and peripheral components (Hofhaus et al., 1991) . The NADH recognition site is believed to reside in the hydrophilic arm of the enzyme, which projects into the mitochondrial matrix. The rotenone site, localized to the membrane adjacent to the ubiquinone binding site (Pilkington et al., 1993) , is a substantial distance from the NADH site. After reduction by NADH, conformational changes in complex I have been demonstrated by crosslinking experiments (Belogrudov and Hatefi, 1994) . In addition, NADH modifies electron spin resonance spectra of complex I, consistent with structural alterations in the region of Fe-S cluster 2 . Autoradiographic Assay of Complex (deJong et al., 1994) . Although the mechanism of NADH enhancement of binding remains to be defined, enzyme reduction likely induces conformational changes that facilitate access of ["HIDHR to the membrane-based recognition site. Because NADH binding to the "proximal" hydrophilic portion of the enzyme modulates the binding of [3H]DHR to the "distal" hydrophobic segment, the response to NADH can be used to probe the ability of the enzyme complex to undergo allosteric modification. Only reduced adenine nucleotides are capable of inducing these changes in complex I, as NAD+ minimally affected ["HIDHR binding. Within the brain, there were marked regional differences in the clegree to which NADH enhanced binding. In those structures in which full saturation studies were performed without and with NADH, the increase in B,,, varied from 600% in str to 900% in cmol. This difference in NADH response was even more striking when brain was compared with other organs. In non-neural tissue, the average enhancement was only 82% (Table 4 ). The reasons for these differences are not known, but are unlikely to be related to different levels of residual NADH because extensive prewashes did not alter binding. It has been suggested that there may be tissue-specific isozymes of complex I (Clay and Ragan, 1988) . Regional variations in the EC,,, values for NADH and NADPH, and in the affinities of rotenone and dihydrorotenone, provide further support for this hypothesis.
The binding of [7H]DHR is also enhanced by NADPH. Direct oxidation of NADPH by complex I has been reported by Hatefi (1973) . In those studies, the pattern of Fe-S cluster reduction suggested entry of reducing equivalents at a site distinct from NADH. In addition, adjacent to complex I in the mitochondrial membrane is NAD(P)H transhydrogenase (Hatefi and Hanstein, 1973) . Conceivably, transfer of hydride ions from NADPH to endogenous NAD+ could contribute to this phenomenon.
['H]DHR binding is heterogeneously distributed in the brain as are two other enzymes of the ETC, succinate dehydrogenase (complex II; Pandykula, 1952) and cytochrome oxidase (complex IV; Hevner et al., 1995) . The density of ["HIDHR binding sites varied more than lo-fold across brain regions. As with other ETC enzymes, complex I appears to be concentrated in neurons; binding in white matter structures is negligible, even under enhanced conditions. In addition, the highest levels of binding in brain are found in the epl, dg, and cmol, which are relatively acellular regions with high densities of excitatory synapses. This finding is consistent with the work of Wong-Riley (1989) showing that cytochrome oxidase is preferentially concentrated in synaptic terminals and dendrites. A distant lesion of entorhinal cortex, which removes synaptic input to a portion of the dg, dramatically decreases binding in this region and lends support to the contention that a substantial portion of complex I (50%) is associated with synaptic terminals. Functional studies also support the notion that ETC enzymes, including complex I, are concentrated in regions of high synaptic density. For example, experimental manipulations that alter neuronal firing patterns across several synapses result in alterations of succinate dehydrogenase and cytochrome oxidase activity (Wong-Riley, 1979; Marshall et al., 1981; Porter et al., 1994; Blandini and Greenamyre, 1995) . We have shown recently that ["HIDHR binding to complex I regulates regionally in a manner identical to these other enzymes (Blandini et al., 1995) .
The assay described in this report may be useful for studying human neurological disorders. Selective defects in complex I have been implicated in the pathogenesis of MPTP-induced parkinsonism (Nicklas et al., 1985) , idiopathic Parkinson's disease (Schapira et al., 1990b), Leber's hereditary optic neuropathy (Smith et al., 1994) , and idiopathic dystonia (Benecke et al., 1992) . Previously, there has been no technique that could provide quantitative information about complex I with a high degree of anatomic precision.
[3H]DHR autoradiography has this capability, but it is not without limitations. Enzyme activity is not measured in our assay. Instead, quantitative information about the rotenone binding site of complex I is obtained. Nonetheless, because rotenone inhibition defines the activity of complex I, defects in ['HIDHR binding can be expected to reflect functional changes in the enzyme. Moreover, the modulatory effect of NADH provides an indication of the functional integrity of the complex-its ability to regulate allosterically.
In summary, we have developed and characterized an assay for complex I based on the binding of ["H]DHR to the enzyme. ['HIDHR binding is specific, saturable, and has the pharmacological profile of a ligand interacting with the rotenone site. Binding in brain is enhanced by NADH, apparently by an allosteric mechanism that reveals more binding sites. Autoradiography of ["HIDHR binding to brain sections provides a simple, reproducible method for obtaining, with excellent spatial resolution, quantitative information about complex I.
